Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group st (Q79765442)
Jump to navigation
Jump to search
scientific article published on 01 November 2008
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group st |
scientific article published on 01 November 2008 |
Statements
Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study (English)
Paul Emery
Bernard Combe
Vibeke Strand
Edward Keystone
Désireé van der Heijde
David Mason
Robert Landewé
Ronald Van Vollenhoven
Philip Mease
1 November 2008